Clinical stage biopharmaceutical company: Bio-Path Holdings, Inc. (BPTH)

Bio-Path Holdings, Inc. (NASDAQ: BPTH) was founded in 2007 and is headquartered in Bellaire, Texas, USA. It has 9 full-time employees. It is an American clinical and preclinical oncology professional RNAi nanoparticle drug development company.

Bio Path Holdings

Bio-Path Holdings, Inc. (BPTH):

The product developed by Bio-Path Holdings is based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, a deoxyribonucleic acid (DNA) backbone modification designed to protect DNA from damage.

Bio-Path Holdings’ main drug candidate is prexigebersen, which is in phase II clinical trials for the treatment of acute myeloid leukemia and chronic myeloid leukemia; preclinical studies of solid tumors include breast and ovarian cancer.

Bio-Path Holdings is also developing liposome Bcl2 for the treatment of lymphoma; and liposome Stat3, which are in the preclinical stage of pancreatic cancer treatment.

The license agreement between Bio-Path and the University of Texas on the antisense nucleic acid delivery technology platform includes two single nucleic acid drug products.

Notify of
Inline Feedbacks
View all Intels

Israeli clinical stage biopharmaceutical company: Can-Fite BioPharma (CANF)

China concept stocks: China Lending Corporation (CLDC), a small loan company